Volume 26, Number 7—July 2020
Surveillance and Testing for Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, March 2016–March 2019
|2015 case definition||2018 case definition|
|Acute respiratory illness with clinical and/or radiologic evidence of pulmonary parenchymal disease (pneumonia or ARDS)
||Severe pneumonia (severity score >3 points) or ARDS (based on clinical or radiologic evidence)
|A hospitalized patient with healthcare-associated pneumonia based on clinical or radiologic evidence
||Unexplained deterioration of a chronic condition of patients with congestive heart failure or chronic kidney disease on hemodialysis
|Upper or lower respiratory illness within 2 weeks after exposure to a confirmed or probable case of MERS-CoV infection
||Acute febrile illness (temperature >38°C) with or without respiratory symptoms AND epidemiologic link†,‡
|Unexplained acute febrile illness (temperature >38°C) AND body aches, headache, diarrhea, or nausea/vomiting, with or without respiratory symptoms, AND leucopenia (white blood cells <3.5 × 109/L) and thrombocytopenia (platelets <150 × 109/L)
||Gastrointestinal symptoms (diarrhea or vomiting) AND leucopenia (white blood cells <3.5 × 109/L) or thrombocytopenia (platelets <150 × 109/L) AND epidemiologic link†,‡
|unexplained severe pneumonia or meets >1 of the above case definition categories and in 14 days prior to symptom onset, has exposure to camels or camel products or to a confirmed or suspected MERS-CoV case-patient.|
*Case definitions apply to adults only (>14 years of age) unless indicated. ARDS, acute respiratory distress syndrome; MERS-CoV, Middle East respiratory syndrome.
†Applies to children and adults.
‡Epidemiologic link defined as, within 14 days before symptom onset, exposure to a person with a confirmed case of MERS-CoV infection, visit to a healthcare facility where any MERS-CoV patient has been identified or treated within the preceding 2 weeks, or contact with dromedary camels or consumption of camel products.